22/09/2026
Platelet-Rich Plasma (PRP) and Mesenchymal Stem Cell (MSC) therapy are both regenerative treatments, but they work through different biological mechanisms.
PRP is created by concentrating platelets and growth factors from a patient's own blood. Because the treatment relies on the body's existing cells, its effects are typically localized and shorter in duration, which is why repeat sessions are often required.
MSCs are living, multipotent cells sourced from Wharton's jelly, the connective tissue inside the umbilical cord. Unlike PRP, MSC therapy does not require drawing blood or tissue from the patient. The cells are administered directly and can act both locally and systemically, supporting a broader range of conditions, from moderate concerns to more complex, chronic cases. In many cases, a single treatment can produce longer-lasting results. Growth factors can also be incorporated into an MSC protocol depending on the condition being treated.
At Alevy, we work exclusively with high-dose, Wharton's jelly-derived MSCs, sourced from screened newborn donors and processed in an ISO-certified laboratory.
Understanding the mechanism behind each therapy, not just the marketing language around it, is what allows patients to make an informed decision.